KR100220322B1 - 장질환 치료를 위한 서방성 경구 투약 제형 - Google Patents

장질환 치료를 위한 서방성 경구 투약 제형 Download PDF

Info

Publication number
KR100220322B1
KR100220322B1 KR1019930702488A KR930702488A KR100220322B1 KR 100220322 B1 KR100220322 B1 KR 100220322B1 KR 1019930702488 A KR1019930702488 A KR 1019930702488A KR 930702488 A KR930702488 A KR 930702488A KR 100220322 B1 KR100220322 B1 KR 100220322B1
Authority
KR
South Korea
Prior art keywords
coating
formulation
drug
granules
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019930702488A
Other languages
English (en)
Korean (ko)
Other versions
KR930702963A (ko
Inventor
로데스 죤
케네쓰 에반스 브라이언
Original Assignee
케네쓰 에반스 브라이언
로데스 죤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케네쓰 에반스 브라이언, 로데스 죤 filed Critical 케네쓰 에반스 브라이언
Publication of KR930702963A publication Critical patent/KR930702963A/ko
Application granted granted Critical
Publication of KR100220322B1 publication Critical patent/KR100220322B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019930702488A 1991-02-22 1992-02-21 장질환 치료를 위한 서방성 경구 투약 제형 Expired - Fee Related KR100220322B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9103795A GB2253346A (en) 1991-02-22 1991-02-22 Delayed release oral dosage forms for treatment of intestinal disorders
GB9103795.2 1991-02-22
PCT/GB1992/000318 WO1992014452A1 (en) 1991-02-22 1992-02-21 Delayed release oral dosage forms for treatment of intestinal disorders

Publications (2)

Publication Number Publication Date
KR930702963A KR930702963A (ko) 1993-11-29
KR100220322B1 true KR100220322B1 (ko) 1999-09-15

Family

ID=10690451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930702488A Expired - Fee Related KR100220322B1 (ko) 1991-02-22 1992-02-21 장질환 치료를 위한 서방성 경구 투약 제형

Country Status (23)

Country Link
US (1) US5401512A (enExample)
EP (1) EP0572486B1 (enExample)
JP (1) JP2958116B2 (enExample)
KR (1) KR100220322B1 (enExample)
AT (1) ATE129893T1 (enExample)
AU (1) AU652032B2 (enExample)
CA (1) CA2104686C (enExample)
CZ (1) CZ281792B6 (enExample)
DE (1) DE69205971T2 (enExample)
DK (1) DK0572486T3 (enExample)
ES (1) ES2079183T3 (enExample)
FI (1) FI105255B (enExample)
GB (1) GB2253346A (enExample)
GE (1) GEP19971086B (enExample)
GR (1) GR3018455T3 (enExample)
HU (1) HU219449B (enExample)
IE (1) IE74225B1 (enExample)
IL (1) IL101036A (enExample)
IN (1) IN179089B (enExample)
NO (1) NO307405B1 (enExample)
NZ (1) NZ241687A (enExample)
WO (1) WO1992014452A1 (enExample)
YU (1) YU17892A (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542299B1 (en) * 1991-11-15 1999-08-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ester linkage containing polymers for use in pharmaceutical preparations
US5322697A (en) * 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
AUPN327695A0 (en) * 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5908912A (en) * 1996-09-06 1999-06-01 Ppg Industries Ohio, Inc. Electrodepositable coating composition containing bismuth and amino acid materials and electrodeposition method
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
NZ513037A (en) 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001032148A1 (en) 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
AU2001239841B2 (en) 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
IT1318376B1 (it) * 2000-03-07 2003-08-25 Pharmatec Internat S R L Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo.
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
US6824559B2 (en) * 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2830446B1 (fr) * 2001-10-09 2004-02-06 Univ Pasteur Composition pharmaceutique destinee a liberer une substance active au niveau du colon
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20060222700A1 (en) * 2005-04-05 2006-10-05 Groenewoud Pieter J Tablet and capsule form of liquid active ingredient
KR20080007586A (ko) * 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 세균감염증의 치료를 위한 세팔로스포린 함유 조절 방출조성물
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
PL2493471T3 (pl) * 2009-10-26 2020-10-19 Borody Nowa skojarzona terapia jelitowa
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
EP2968151B1 (en) 2013-03-13 2017-04-19 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
HK1218856A1 (zh) 2013-03-15 2017-03-17 Warner Chilcott Company, Llc 用於减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物
WO2018013957A1 (en) * 2016-07-14 2018-01-18 Greco Chad Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
FR2426477A1 (fr) * 1978-05-26 1979-12-21 Monsanto Co Composition de retardement d'incendie comprenant notamment du sulfate d'ammonium et un ether carboxyalkylique ou hydroxyalkylique d'un polygalactomannane
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
DE69020758T2 (de) * 1989-03-10 1995-12-07 Yamanouchi Pharma Co Ltd Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
JPH0334929A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与用組成物
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル

Also Published As

Publication number Publication date
AU1279592A (en) 1992-09-15
IN179089B (enExample) 1997-08-23
FI105255B (fi) 2000-07-14
EP0572486A1 (en) 1993-12-08
ES2079183T3 (es) 1996-01-01
NZ241687A (en) 1993-09-27
IL101036A (en) 1996-05-14
CA2104686A1 (en) 1992-08-23
KR930702963A (ko) 1993-11-29
US5401512A (en) 1995-03-28
HU9302379D0 (en) 1993-11-29
CA2104686C (en) 2000-05-02
GB2253346A (en) 1992-09-09
EP0572486B1 (en) 1995-11-08
IL101036A0 (en) 1992-11-15
NO932979L (no) 1993-08-20
IE74225B1 (en) 1997-07-16
FI933680A0 (fi) 1993-08-20
IE920548A1 (en) 1992-08-26
DE69205971T2 (de) 1996-04-11
CZ281792B6 (cs) 1997-01-15
ATE129893T1 (de) 1995-11-15
AU652032B2 (en) 1994-08-11
HU219449B (hu) 2001-04-28
FI933680L (fi) 1993-08-20
JP2958116B2 (ja) 1999-10-06
GR3018455T3 (en) 1996-03-31
HUT65914A (en) 1994-07-28
JPH06505246A (ja) 1994-06-16
GEP19971086B (en) 1997-12-02
CZ162693A3 (en) 1994-10-19
NO307405B1 (no) 2000-04-03
DE69205971D1 (de) 1995-12-14
DK0572486T3 (da) 1995-12-11
GB9103795D0 (en) 1991-04-10
WO1992014452A1 (en) 1992-09-03
YU17892A (sh) 1994-12-28
NO932979D0 (no) 1993-08-20

Similar Documents

Publication Publication Date Title
KR100220322B1 (ko) 장질환 치료를 위한 서방성 경구 투약 제형
JP3194974B2 (ja) 標的制御釈放薬剤
EP0825854B1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827398B1 (en) Pharmaceutical dosage form for colonic delivery
EP1916995B1 (en) Ph-controlled pulsatile delivery system, methods for preparation and use thereof
CN101125134B (zh) 盐酸坦洛新缓释胶囊及其制备方法
KR20000053326A (ko) 결장내 운반에 사용되는 다층 장용성 중합체 코팅물을 갖는 약제학적 제형
EP0956006A1 (en) Colonic delivery of weak acid drugs
RU2412694C2 (ru) pH-КОНТРОЛИРУЕМЫЕ СИСТЕМЫ ИМПУЛЬСНОЙ ДОСТАВКИ, МЕТОДЫ ПОЛУЧЕНИЯ И ИХ ИСПОЛЬЗОВАНИЯ
AU7732496A (en) Pharmaceutical dosage form for colonic delivery
KR20090128918A (ko) 염산 알푸조신이 함유된 서방형 제제의 제조
MXPA99003093A (en) Colonic delivery of weak acid drugs
WO1994007503A1 (en) Enteric preparations
NZ565272A (en) pH-controlled pulsatile delivery system, methods for preparation and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20100610

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110622

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110622